THIS IS A REPOST TO COMPLY WITH RULE #1. (HOPEFULLY )
This is related to Pizzagate because one reason the elite traffic in children is to harvest body parts for medical purposes.
John Podesta's friend and orthopedic hand doctor is on the board of 'TissueGene', who along with their Korean affiliate, Kolon Life Sciences, are companies that develop regenerative therapies using donor tissue.
Could it be that they get their supply of human tissue from the children they abduct?
From this article you can see that the human tissue is big business.
'Promising Hope for Those in Need of Human Tissue and Organs: Rockwell Automation to Innovate Advanced Production Technologies at Department of Defense’s New Manufacturing Institute'
"UVA and Partners Have a Bold Goal: Manufacturing Human Tissue'
University of Virginia biomedical engineers and physicians have earned a role in a new, national initiative that will develop technologies for manufacturing human tissues and organs, with the goal of making them readily available to patients. A public-private effort, the Advanced Regenerative Manufacturing Institute brings together a consortium including UVA and nearly 100 other partners from industry, government, academia and the non-profit sector. The consortium will lead the Advanced Tissue Biofabrication Manufacturing USA Institute on behalf of the U.S. Department of Defense. The federal government will provide approximately $80 million, and the partner organizations combined will contribute more than $200 million to support the development of tissue and organ manufacturing capabilities.
From WikiLeaks archives of John Podesta emails, there is a string regarding Podesta corresponding with his Orthopedic hand doctor, Mustafa A. Haque, who apparently is a good enough of a friend to register Podesta in the Cherry Blossom race and even offer to train with him on the weekends.
Hope you are doing well. Please feel free to call me at 301-787-1040 if you have any problems with your hand wounds. I was having some trouble downloading pictures from my phone, so I will work on getting you the surgery pictures this weekend.
Your guaranteed entry and the website to register for the cherry blossom are: GC-73QHCW-81
https://secure5.marathonguide.com/register/CherryBlossom10Mile/EntryByCode.cfm John P.
The deadline for registration is March 1.
Looking forward to a good run. I'm not sure if I can keep up with you, but let me know if you're ever looking for company to do a training run on the weekends.
Take care, Mustafa
I've been doing well, but fear that the little finger may be getting infected. I saw Daniel Saturday and this morning and all seemed fine except the place where the finger joins the palm continues to weep. As always, thanks for everything including the cherry blossom admission!
SO WHAT ABOUT MUSTAFA A. HAQUE? HE IS A BOARD MEMBER OF TISSUEGENE, INC
Executive Profile Mustafa A. Haque M.D. Member of Clinical Advisory Board, TissueGene, Inc.
TissueGene, Inc. is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the company’s core technology employs a form of cell therapy to deliver therapeutic proteins directly to localized areas of damaged tissue. The sustained expression of such proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D and TG-N for the regeneration of cartilage, bone, disc and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.
WHO DOES TISSUEGENE COLLABORATE WITH? A KOREAN BASED COMPANY
Kolon Life Science, Inc. (KOSDAQ: 102940), a subsidiary of the Kolon Group, is a leading Korean-based biochemical company focused on pharmaceutical ingredients and environmental biochemicals. Its pharmaceutical division provides active ingredients and intermediates ranging from zaltoprofen and flurbiprofen to argatroban and voglibose. In Asia, TissueGene has licensed intellectual property rights to Kolon Life Science (KLS) for commercialization of TG-C and TG-B. Through Kolon Life Science, TissueGene has been able to expedite commercialization of its products by conducting clinical trials in both the US and Korea. For more information, please visit http://www.kolonls.co.kr/english.
WHAT IS TG-C? (NOTICE THE WORD DONOR)
TG-C is an allogeneic (donor) cell therapy involving human chondrocytes (cartilage cells) that have been genetically modified to produce the therapeutic growth factor TGF-ß1 and has been developed to induce cartilage regeneration in patients with osteoarthritis. Chondrocytes, when stimulated by the transforming growth factor beta 1 (TGF-ß1), have been shown to play a critical role in both the formation and maintenance of articular cartilage by regulating the homeostasis of the hyaline cartilage matrix.
In 2006 NBC wrote about using body of the dead without permission, which shows that it has been big business for quite some time.
'Grotesque scandal like a 'cheap horror movie' Body-parts company spread disease, desecrated the dead for profit'